FGF2 and pancreatic ductal adenocarcinoma: This finding is opposite to studies in other cancer types especially cancers with desmoplastic stroma such as pancreatic ductal adenocarcinoma (PDAC) where BET inhibitors were predominantly shown to decrease FGF2 expression and secretion of inflammatory cytokines from the TME as a mechanism inducing the anti‐tumor effects of BET inhibitors (Yamamoto et al, 2016; Leal et al, 2017).